EMA recommends extension of therapeutic indications for trastuzumab deruxtecan
esmo - New indication concerns monotherapy in the adjuvant treatment for adult patients with resected HER2-positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2-targeted treatment
AI Summary: The EMA has recommended expanding therapeutic indications for trastuzumab deruxtecan (Enhertu), updating its EPAR to reflect new evidence supporting wider clinical use across additional HER2‑expressing tumours. Regulators’ endorsement could increase patient access while clinicians watch for ADC class toxicities and await implementation details from national authorities.
Related Stories
CA017‑078 results prompt reevaluation of perioperative nivolumab in MIBC / 3 hrs
Trastuzumab rezetecan (HORIZON‑Breast06) slashes progression risk by 73% / 16 hrs
ENZAMET trial confirms long-term survival benefit of enzalutamide in mHSPC / 2 months
Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 3 months
Teclistamab shows survival benefit prompting earlier use discussions / 4 months
CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 6 months
Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 6 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Cancer Research, Infant Health, Cybersecurity, Vitamin D and look for the RSS link.
StackHealth Time Machine